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Abstract
Background: Obesity is an important cause of multiple cancer types, amongst which endometrial cancer (EC). The
relation between obesity and cancer is complicated and involves alterations in insulin metabolism, response to
inflammation and alterations in estradiol metabolism. Visceral obesity is assumed to play the most important role in
the first two mechanisms, but its role in estradiol metabolism is unclear. Therefore, this retrospective study explores
the relationship of body mass index (BMI), visceral fat volume (VAV) and subcutaneous fat volume (SAV) and serum
levels of sex steroids and lipids in patients with endometrial cancer.
Methods: Thirty-nine postmenopausal EC patients with available BMI, blood serum and Computed Tomography
(CT) scans were included. Serum was analyzed for estradiol, dehydroepiandrosterone sulfate (DHEAS),
androstenedione, testosterone, cholesterol, triglycerides and high (HDL), low (LDL) and non-high density (NHDL)
lipoprotein. VAV and SAV were quantified on abdominal CT scan images. Findings were interpreted using pearson
correlation coefficient and linear regression with commonality analysis.
Results: Serum estradiol is moderately correlated with BMI (r = 0.62) and VAV (r = 0.58) and strongly correlated with
SAV (r = 0.74) (p < 0.001 for all). SAV contributes more to estradiol levels than VAV (10.3% for SAV, 1.4% for VAV,
35.9% for SAV and VAV, p = 0.01). Other sex steroids and lipids have weak and moderate correlations with VAV or
SAV.
Conclusions: This study shows that serum estradiol is correlated with BMI and other fat-distribution measures in
postmenopausal endometrial cancer patients. Subcutaneous fat tissue contributes more to the estradiol levels
indicating that subcutaneous fat might be relevant in endometrial cancer carcinogenesis.
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Background
Endometrial cancer (EC) is the most common
gynecological cancer in developed countries with an an-
nual incidence rate of 320,000 cases world-wide [1]. Obes-
ity is the most important risk factor for EC as current
estimates attribute 40% of new EC cases to obesity [2, 3].
Consequently, the increase in obesity has caused a concur-
rent increase in EC incidence in the last decades [4–6].
The biological relation between obesity and cancer is
complex, and involves alterations in insulin metabolism,
inflammatory response and sex steroid metabolism [7, 8].
EC occurs predominantly in postmenopausal women in
which estrogen formation mainly depends on the aroma-
tase activity in fat [9, 10]. Androstenedione and testoster-
one are the main substrates for aromatization into estrone
and estradiol (E2). Dehydroepiandrosterone sulfate
(DHEAS) produced by the adrenal gland is the main
source of androstenedione and testosterone. Although E2
is more potent than E1, E1 is the most abundant form of
estrogen in postmenopausal women. E2 is either synthe-
sized directly from testosterone by aromatase, or through
reduction of E1 [9]. Estradiol induces endometrial prolifer-
ation which, in the absence of progesterone, may lead to
endometrial cancer [7, 8]. EC is traditionally classified into
endometrioid (EEC) and non-endometrioid endometrial
cancer (NEEC). EEC carcinogenesis is driven by estradiol,
while NEEC is assumed to develop independent of
estrogens, although recent data suggests that estradiol
might also play a role in NEEC tumorigenesis [11–13].
Obesity is quantified with the body mass index (BMI),
yet BMI does not reflect the fat distribution in the
visceral abdominal volume (VAV) and subcutaneous
abdominal volume (SAV). VAV is assumed to be meta-
bolically more active than SAV, and is involved in pro-
duction of cytokines and release of free fatty acids that
contribute to inflammation and alterations in insulin
metabolism associated with metabolic syndrome and risk
of EC [8, 14]. However, the role of VAV and SAV in the
production of sex steroids and lipids in EC patients is
unknown [15–17]. VAV and SAV can reliably be quanti-
fied using abdominal computed tomography (CT) scans
[18]. Previous studies have reported a relation between
SAV and development of EC, while VAV was associated
with adverse outcome [19–21]. However, neither serum
sex steroids nor lipid levels were measured in these
studies. Therefore the aim of this study was to explore
the relation between BMI, visceral and subcutaneous fat
volumes and serum levels of sex steroids and lipids in
endometrial cancer patients.
Methods
Aim, design and setting
The objective of this study was to explore the relation
between BMI, visceral and subcutaneous fat volumes
and serum levels of sex steroids and lipids in endo-
metrial cancer patients. To that end, a retrospective
study was performed in the Radboud university med-
ical center, a tertiary gynecologic oncology center in
the Netherlands.
Patients
All surgically treated postmenopausal patients with
endometrial cancer were eligible if they had no history
of hormonal treatment or contraceptive use within 3
months prior to diagnosis. From the Radboudumc bio-
bank, a total of 48 postmenopausal EC patients treated
between 1999 and 2009 was included. Nine patients
were excluded: three because no preoperative serum was
available and six because no preoperative CT was
available, leaving 39 patients for analysis. All patients
underwent primary hysterectomy with bilateral salpingo-
oophorectomy and lymphadenectomy was performed if
indicated [22]. Patients were staged according to the
International Federation of Gynaecology and Obstetrics
(FIGO) staging criteria [23]. Adjuvant radiotherapy or
chemotherapy was given in case of high risk factors.
Tumours were classified into EEC and NEEC and
reviewed by an expert pathologist (J.B.).
Baseline characteristics were extracted from patient
records including patient and tumor characteristics and
CT-scan results. FIGO stage I-II was defined as early
stage and FIGO stage III-IV as advanced stage. BMI was
based on measured weight and height or patient re-
ported weight and height at diagnosis. The study was
carried out in accordance with the Declaration of
Helsinki and was approved by the Local Ethical
Committee of Radboudumc. All patients gave written in-
formed consent for use of clinical data and tissue before
entry in the Radboudumc biobank.
Fat distribution
CT scan images were analyzed at the University Hospital
Bergen, Norway using a semi-automated method for
volumetric quantification of abdominal fat (iNtuition
software program, TeraRecon Inc., San Mateo, CA,
USA). This program estimates VAV and SAV based on
cross-sectional CT scan images from the upper right
diaphragm to L5/S1 level using segmentation of pixels
with values for Hounsfield units (HU) corresponding to
fat tissue (− 195 to − 45 HU) [18]. The correct segmen-
tation of SAV and VAV was visually verified by the
operator (W.W.), and manually adjusted if necessary as
illustrated in Fig. 1. The sum of SAV and VAV was con-
sidered to comprise the total abdominal fat volume
(TAV, cm3). The percentage of visceral out of total
abdominal fat volume ([VAV/TAV]× 100; VAV%) was
also calculated. Waist circumference (WC) was mea-
sured at the level of vertebral body L3/L4.
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Serum sex steroid and lipid levels
Non fasting blood samples were collected according the
Radboudumc biobank protocol, at the last outpatient
visit prior to surgery. Blood samples were collected in
vacutainer tubes, centrifuged at 200 g during 10min and
stored at − 40 °C until assayed. Analyses of sex steroids
included DHEAS, testosterone, androstenedione (A4)
and E2. The following lipids were analyzed: cholesterol,
high (HDL), low, (LDL) and non-high density lipopro-
tein (NHDL) and triglycerides. DHEAS and E2 (3th
generation) were measured by ECLIA (Electro-chemilu-
minescence immunoassay) on a Modular E170 random
access analyzer (Roche, Basel, Switzerland). A4 and T
were measured using an in-house developed liquid-
chromatography tandem mass spectrometry (LC-MS/
MS) [24]. In case sample measurements were below the
detection level, calculations were performed using the
lower limit of detection divided by 2. Cholesterol (2nd
generation), triglycerides and HDL (3rd generation) were
analyzed by an enzymatic colorimetric method on a
Cobas 6000 random access analyser (Roche, Basel,
Switzerland). LDL was calculated with the Friedewald
formula. NHDL was calculated by subtracting HDL from
cholesterol. All samples were analyzed on the same day.
Statistical analysis
Differences in baseline characteristics, fat distribution
values and serum levels between EEC and NEEC were
compared using the χ2 test for discrete variables and the
Mann Whitney U test for continuous variables. The
correlations between log transformed sex steroid and
lipid levels and fat measures were analyzed using Spear-
man rho’s for not-normally distributed variables and vi-
sualized with scatterplots and regression lines.
Correlations of r > 0.7 were considered strong, correla-
tions between r = 0.4 and r = 0.7 as moderate and corre-
lations of r < 0.4 as weak [25, 26]. Linear regression was
followed by commonality analysis in order to identify
the unique and common contribution of the independ-
ent variables to the variation of the dependant variable
[27]. All tests were two-sided and p-values of < 0.05 were
considered significant. Statistical analyses were performed
using SPSS (version 22.0 for Microsoft, SPSS Inc., Chi-
cago, IL.) and R (version 3.5.1 https://www.r-project.org),
using the yhat package version 2.0.0 [28, 29]. As this study
does not report on clinical outcome, no relevant core out-




Clinicopathological characteristics of the study cohort
(n = 39) are summarized in Table 1. The median age at
diagnosis was 68 years and the median BMI was 26.9 kg/
m2. Patients with NEEC histology (n = 14) were more
frequently diagnosed with advanced stage (71% versus
28%) and recurrence (58% versus 24%) compared to
patients with EEC histology. There was no significant
difference in EC related mortality between patients with
EEC and NEEC.
Correlation of sex steroid- and lipid levels with abdominal
fat volumes
The correlation coefficients of estradiol in relation to fat
volumes showed strong correlations with SAV (r = 0.74,
p < 0.01) and TAV (r = 0.74, p < 0.01) and moderate
correlations with BMI (r = 0.62, p < 0.01), WC (r = 0.64,
p < 0.01) and VAV (r = 0.58, p < 0.01) (Table 2). A4 had a
moderate correlation with SAV (r = 0.43, p < 0.01) and
had weak correlations with WC and TAV (r = 0.33
and 0.37, both p < 0.05). DHEAS was weakly corre-
lated with BMI, VAV and SAV (r = 0.36, r = 0.35 and
0.34, all p < 0.05; Table 2).
Fig. 1 Representative examples of CT scan results. Visceral fat in green and subcutaneous fat in purple. CT scan on the left with high VAV, CT
scan on the right with high SAV
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HDL had a moderate negative correlation with TAV
(r = − 0.45, p < 0.01) and SAV (r = − 0.42, p < 0.01) and a
weak negative correlation with WC (r = − 0.37, p < 0.05)
and VAV (r = − 0.39, p < 0.05). Triglycerides showed a
weak correlation with the proportion of VAV in relation
to TAV (VAV%) (r = 0.36, p < 0.05), but not with VAV or
SAV (Table 2).
Within the individual sex steroids there were
moderate correlations between A4 and DHEAS and A4
and testosterone (Additional file 1: Table S1). Strong
correlations between lipids occurred between cholesterol
and LDL, cholesterol and NHDL, and LDL and NHDL
(Additional file 1: Table S2). Correlations of fat distribu-
tion measures are shown in Additional file 1: Table S3.
Sex steroids, lipids and fat distribution in endometrioid
and non-endometrioid histology
No significant differences in fat distribution measure-
ments were observed between patients with EEC and
NEEC (Table 3). The EEC subgroup had significantly
higher serum levels of cholesterol, LDL and NHDL com-
pared to the NEEC group without significant differences
in sex steroid levels (Table 3).
Estradiol had a moderate correlation with BMI in both
EEC and NEEC patients (r = 0.65, p0.007 and 0.69,
p < 0.0001; Fig. 2). Estradiol was strongly correlated
with VAV (r = 0.72, p < 0.0001) in EEC, but had only a
weak correlation in NEEC (r = 0.35, p0.224; Fig. 2),
whereas SAV was strongly correlated in both EEC and
NEEC patients (r = 0.74, p < 0.005 and 0.73, p < 0.0001;
Fig. 2).
Contribution of VAV and SAV to production of estradiol
Based on the commonality analysis in the multiple linear
regression model of estradiol in relation to SAV and
VAV, most of the variation in estradiol levels was
explained by SAV and VAV together, due to the strong
correlation between SAV and VAV (r = 0.85, p < 0.001).
In the study cohort, the total explained variation in es-
tradiol levels was 47.6%: the unique contribution of SAV
was 10.3% (significant at p = 0.01), VAV explained 1.4%
(p = 0.33) [27], and the common contribution was 35.9%.
There was no significant difference between the EEC
and NEEC subgroups (p = 0.64).
Discussion
The link between obesity and endometrial cancer is
explained by three potential mechanisms: (1) secretion
of free fatty acids leading to increased levels of insulin
and insulin growth factor, (2) production of cytokines
that lead to a persistent inflammatory environment and
(3) alterations in estradiol metabolism. In the current
study a positive correlation was observed between serum
estradiol levels and BMI and other fat measures in endo-
metrial cancer patients. Furthermore, we observed a
stronger correlation of subcutaneous fat volume (SAV)
with estradiol when compared to visceral fat volume
(VAV). Finally, SAV was more contributive to the
estradiol levels than VAV.
Estradiol plays an important role in the oncogenesis of
hormone dependent cancers like postmenopausal breast
cancer and endometrial cancer through its proliferative
activity in the target tissue. In endometrial cancer, the
absence of counteractive effects of progesterone on the
endometrium in postmenopausal women, leads to
endometrial hyperplasia and eventually endometrioid
type endometrial cancer [11]. The role of estradiol is
supported by the higher incidence of EC observed in
patients with exogenous estrogen use, and is in line with
Table 1 Clinicopathological characteristics of study cohort
Total, n = 39 EEC, n = 25 NEEC, n = 14 p
Age (years)a 68 (50–88) 68 (50–85) 74,5 (54–82) 0.098
BMI (kg/m2)a 26.9 (20–51) 27.5 (20–51) 25.7 (22–37) 0.289
Follow-up (months)a 34 (1–168) 34 (1–88) 30 (2–168) 0.946
Hypertensionb 0.133
Yes 17 9 (36%) 8 (62%)
No 21 16 (64%) 5 (38%)
Diabetes mellitusb 0.825
Yes 8 (21%) 5 (20%) 3 (23%)
No 30 (79%) 20 (80%) 10 (77%)
Tumor grade
1 4 (10%) 4 (16%)
2 16 (41%) 16 (64%)
3 19 (48%) 5 (20%) 14 (100%)
Histology
Endometrioid 25 (64%) 25 (64%)
Non-endometrioid 14 (36%) 14 (36%)
Serous 2 (5%) 2 (5%)
Clear cell 2 (5%) 2 (5%)
Mixed 5 (13%) 5 (13%)
Carcinosarcoma 5 (13%) 5 (13%)
FIGO stage 0.009*
Early (I-II) 22 (56%) 18 (72%) 4 (29%)
Advanced (III-IV) 17 (44%) 7 (28%) 10 (71%)
Recurrencec 0.041*
Yes 13 (33%) 6 (24%) 7 (58%)
No 24 (62%) 19 (76%) 5 (42%)
EC related death 0.542
Yes 9 (23%) 5 (20%) 4 (29%)
No 30 (77%) 20 (80%) 10 (71%)
*significant result, a Median value (range) b data missing in one patient, c data
missing in two patients
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the known endogenous estrogen related risk factors i.e.
nulliparity, early menarche, late menopause and high
BMI [30–32]. Recently, EC patients were shown to have
higher serum levels of estradiol compared to healthy
controls [17, 33]. Our study is the first to evaluate the
correlation of fat measures with serum estradiol in EC
patients. Additionally, our results indicate that SAV has
a more important role in estradiol production than VAV.
Hetemaki et al. and Wang et al. have reported that estra-
diol levels within VAV and SAV did not differ in studies
in healthy postmenopausal and obese premenopausal
women [15]. However, Wang et al also showed a higher
CYP19A1 expression in SAV compared to VAV among
obese premenopausal women undergoing bariatric
surgery. CYP19A1 encodes for the aromatase enzyme,
which suggest that a higher aromatase activity could
explain the more important role of SAV in estradiol
metabolism [34].
Several studies have suggested a synergistic activity of
estradiol and insulin in the endometrioid endometrial
Table 2 Correlation coefficients of steroid and lipid serum levels and fat measurements
BMI WC TAV VAV SAVa VAV%b
Sex steroids
Estradiol (pmol/L) .62** .64** .74** .58** .74** −.06
Androstenedione (nmol/L) .26 .33* .37* .29 .43** −.17
Testosterone (nmol/L) .17 .31 .29 .19 .31 −.15
DHEAS (μmol/L) .36* .31 .30 .35* .34* −.10
Lipids
Cholesterol (mmol/L) −.07 −.08 −.19 −.08 −.20 .01
HDL (mmol/L) −.23 −.37* −.45** −.39* −.42** −.15
LDL (mmol/L) −.03 −.03 −.13 −.02 −.12 −.01
NHDL (mmol/L) −.00 .01 −.08 .01 −.09 .05
Triglycerides (mmol/L) −.05 .17 .15 .14 .09 .36*
Chol/HDL ratio .17 .27 .29 .30 .27 --.13
a SAV analysis is limited to 38 patients, b proportion of VAV in relation to TAV, * p < 0.05, **p < 0.01
Table 3 Fat distribution measurements and serum levels of study cohort
Total, n = 39 Median (SD) EEC, n = 25 Median (SD) NEEC, n = 14 Median (SD)
Fat distribution
BMI (kg/m2) 26.9 (7.9) 27.5 (9.0) 26.1 (4.7)
WC (cm) 95.3 (15.8) 97.8 (17.9) 93 (11.0)
TAV (cm3) 7529 (4633) 7487 (5161) 7570 (3484)
VAV (cm3) 2772 (1677) 2861 (1741) 2668 (1610)
SAV (cm3) 4544 (3230) 4556 (3669) 4544 (2181)
VAV% (%) 33.4 (8.2) 32.5 (8.3) 34.4 (8.2)
Sex steroids
Estradiol (pmol/L) 54 (38.4) 49 (43.8) 56 (27.2)
Androstenedione (nmol/L) 1.8 (1.1) 1.8 (1.1) 1.7 (1.2)
Testosterone (nmol/L) 0.7 (0.6) 0.7 (0.6) 0.6 (0.4)
DHEAS (μmol/L) 2.4 (1.5) 2.4 (1.3) 2.31 (1.8)
Lipids
Cholesterol (mmol/L) 5.1 (1.4) 5.8 (1.3)* 3.8 (1.4)*
HDL (mmol/L) 0.8 (0.4) 0.8 (0.4) 0.6 (0.4)
LDL (mmol/L) 3.5 (1.2) 3.8 (1.1)* 2.6 (1.2)*
NHDL (mmol/L) 4.3 (1.3) 4.5 (1.3)* 3.2 (1.3)*
Triglycerides (mmol/L) 1.5 (0.6) 1.5 (0.6) 1.5 (0.4)
Chol/HDL ratio 7 (3.4) 7 (3.3) 8 (3.5)
*significant differences at p < 0.05
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carcinogenesis [8, 35, 36]. Alterations in insulin metabol-
ism are mainly mediated by VAV [37, 38]. Combining
this with our results suggests that both SAV and VAV
are relevant for EC carcinogenesis: SAV is primarily re-
sponsible for estradiol production and VAV is involved
in alterations leading to hyperinsulinemia.
With respect to NEEC carcinogenesis, it is interesting
to observe the similar relation between BMI and estra-
diol in EEC and NEEC patients. Up till now, the role of
estradiol in NEEC carcinogenesis is largely unknown
[13, 39–41]. Estradiol might contribute to NEEC
development directly through stimulation of estradiol re-
sponsive parts of heterogenic non-endometrioid tumors,
or indirectly by obesity associated mechanisms such as
alterations in the insulin metabolism or in the inflamma-
tory response [7, 8].
Strengths of this study include the selection of EC pa-
tients with different tumor grades, stages and histology.
Due to the standardized assessment of fat compartments
on CT scans, a highly reproducible and quantitative
analyses could be performed of SAV and VAV. Although
we endorse the findings of this study, there are some
limitations to be addressed. First, the number of cases in
this study is small. Yet, results of our study with respect
to the correlations of fat distribution measurements are
in line with previously published studies with more cases
[19] (Additional file 1: Table S3). Second, as the CT
scans were primarily performed to assess intra-
abdominal tumor spread, SAV was not always com-
pletely visualized in the CT field of view (FOV) making
exact quantification of SAV on some CT scans challen-
ging. As a consequence, one patient who was believed to
have more than 10% of SAV missing, was excluded from
the SAV analyses. Furthermore, when restricting the
analyses to patients in whom all SAV was included in
the FOV, our findings remained the same. The estimated
specific contribution of SAV to serum estradiol could
thus have been even stronger if complete SAV had been
included in the FOV of all patients. Third, our study and
a previous study have found a strong correlation of SAV
with VAV, which hampers identification of separate con-
tributions of SAV and VAV with a general multiple linear
regression model. Therefore, a commonality analysis was
performed to separate the individual contributions of
SAV and VAV as much as possible [19]. Fourth, analyt-
ical imprecision of estradiol at the low serum levels
measured in this study, is relatively high. Therefore, it is
difficult to identify statistically significant differences in
small patient cohorts. Nevertheless, the estradiol levels
in this study were comparable to results found in an-
other study [17]. Since the blood samples donation proto-
col did not require a fasting or non fasting status, serum
lipid levels might not be comparable, thereby hampering
proper analysis of the relation with fat distribution [42].
Yet for estradiol, impact of fasting or time at blood with-
drawal will have no effect on the results as postmenoapau-
sal women have stable estradiol serum levels throughout
the day [43]. A standardized protocol with blood sample
donation on a fixed point of the day with uniformity in
fasting status will enable more reliable analysis of the
relation between lipids and fat distribution.
Conclusions
This study shows that estradiol levels are correlated to
BMI and fat distribution measurements in postmeno-
pausal endometrial cancer patients. The subcutaneous
fat contributes more to estradiol levels than the visceral
fat indicating that subcutaneous fat might be relevant
for endometrial cancer carcinogenesis. Validation of our
findings in a study that evaluates all sex steroids impli-
cated in the estrogen metabolism among patients with
EC and premalignant lesions is warranted before defini-
tive conclusions can be drawn. If high SAV is confirmed
to play a particularly important role in the develop-
ment of endometrial cancer, it may be relevant to ex-
plore it as an independent risk factor for developing
cancer. Also the interplay between estradiol, hyperin-
sulinemia and inflammation in tumorgenesis should
be clarified in order to determine the optimal strategy
to prevent endometrial cancer.
Fig. 2 Correlation of estradiol and fat distribution measures in EEC and NEEC. a: correlation of estradiol and BMI, b: correlation of estradiol and
VAV, c: correlation of estradiol and SAV
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Additional file
Additional file 1: Table S1. Correlations of sex steroids. Table S2.
Correlations between serum lipid levels. Table S3. Correlation between
obesity markers including CT derived fat volumes. (XLSX 10 kb)
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